New promising drug targets in cancer- and mtastasis-initiating cells

Murielle Mimeault, Surinder K. Batra

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations

Abstract

The unique properties of cancer- and metastasis-initiating cells endowed with a high self-renewal and aberrant differentiation potential (including their elevated expression levels of anti-apoptotic factors, multidrug transporters, and DNA repair and detoxifying enzymes) might be associated with their resistance to current clinical cancer therapies and disease recurrence. The eradication of cancer- and metastasis-initiating cells by molecular targeting of distinct deregulated signaling elements that might contribute to their sustained growth, survival, and treatment resistance, therefore, is of immense therapeutic interest. These novel targeted approaches should improve the efficacy of current therapeutictreatments against highly aggressive, metastatic, recurrent, and lethal cancers.

Original languageEnglish (US)
Pages (from-to)354-364
Number of pages11
JournalDrug Discovery Today
Volume15
Issue number9-10
DOIs
StatePublished - May 2010

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'New promising drug targets in cancer- and mtastasis-initiating cells'. Together they form a unique fingerprint.

Cite this